About Respiri
Respiri is a company based in Melbourne (Australia) founded in 1987. Respiri offers products and services including WheezeRate Detector, RPM Programs, and Telehealth Platforms. Respiri operates in a competitive market with competitors including Tyto Care, Edwards Lifesciences, BioIntelliSense, Endotronix and Athelas, among others.
- Headquarter Melbourne, Australia
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vitasora Health Limited
-
Annual Revenue
$2.02 M (USD)580.63as on Jun 30, 2025
-
Net Profit
-$6.6 M (USD)-41.74as on Jun 30, 2025
-
EBITDA
-$6.96 M (USD)-40.59as on Jun 30, 2025
-
Latest Funding Round
$12.5 M (USD), Post-IPO
Oct 20, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Respiri
Respiri is a publicly listed company on the ASX with ticker symbol VHL in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Respiri
Respiri offers a comprehensive portfolio of products and services, including WheezeRate Detector, RPM Programs, and Telehealth Platforms.
FDA-cleared device for remote detection of wheezes in patients.
Customizable programs for monitoring and managing chronic conditions remotely.
HIPAA-compliant platforms for data-driven patient care and interventions.
People of Respiri
Unlock access to complete
Unlock access to complete
Funding Insights of Respiri
Investors in Respiri
Respiri has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Bergen Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Bergen Asset Management is focused on global institutional investments.
|
Locked | Locked | Locked |
Investor details for Respiri
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Respiri
Investment portfolio details for Respiri
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Respiri
Detailed financials for Respiri
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Respiri Comparisons
Peer comparison for Respiri
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Respiri
Respiri operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tyto Care, Edwards Lifesciences, BioIntelliSense, Endotronix and Athelas, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical consultations are facilitated via self-exams and remote diagnostic devices.
|
|
| Locked | Locked | Locked |
Medical devices for structural heart disease are developed and provided.
|
|
| Locked | Locked | Locked |
Vital signs are monitored via a single-use patch and platform.
|
|
| Locked | Locked | Locked |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring.
|
|
| Locked | Locked | Locked |
Provider of smart solutions for monitoring heart rate, weight, and blood pressure
|
|
| Locked | Locked | Locked |
Remote monitoring platform for tracking patient activity
|
Detailed competitors of Respiri
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Respiri
Complete news archive for Respiri
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Respiri
Respiri was founded in 1987 and raised its 1st funding round 24 years after it was founded.
Respiri is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Mario Gattino is the current CEO of Respiri.
Annual revenue of Respiri is $2.02M as on Jun 30, 2025.
Respiri was founded in 1987 in Melbourne, Australia, where tools for detecting respiratory disorders are developed. A range of clinical laboratory and home care products is created by the company within the medical technology sector. The SonoSentry system, an over-the-counter device for automated wheeze detection, is offered, with data upload capabilities to the cloud through a web portal. Leadership is provided by CEO and Director Mario Gattino.
Respiri's top competitors include Tyto Care, Endotronix and Athelas.
Respiri offers WheezeRate Detector, RPM Programs, and Telehealth Platforms.
Yes, Respiri is publicly traded on ASX under the ticker symbol VHL.
Respiri has 1 investor. Key investors include Bergen Asset Management.
The ticker symbol of Respiri is VHL on ASX.